HS research update (2026-06-08): What’s new on PubMed? Canonical URL: https://acneinversa.life/en/blog/hs-research-update-2026-06-08/ Markdown URL: https://acneinversa.life/en/blog/hs-research-update-2026-06-08.md Plain text URL: https://acneinversa.life/en/blog/hs-research-update-2026-06-08.txt Language: en Category: Research Published: 2026-06-08 Last updated: 2026-06-08 Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert) Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, pain, quality of life, surgery, wound care A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice. Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions. Article Publication overview This update includes 8 PubMed publications with abstracts from the monitoring window 2026-05-31 to 2026-06-08. The most common themes are comorbidities, biologics, surgery, wound care, quality of life. - Compared with the previous update: not automatically assessed. - No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window. - This is a research overview, not a guideline update or medical recommendation. Top highlights The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities. - Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.: The abstract describes a systematic review. In practical terms, it focuses on this question or finding: Dietary factors have been suggested to influence inflammatory skin diseases; however, their role in the pathogenesis and clinical course of hidradenitis suppurativa (HS) remains insufficiently understood. Increasing e… What makes it notable here is that it approaches HS through surgery, wound care, comorbidities. The main limitation to keep in mind is: Its strength depends on the quality and comparability of the included studies, and an abstract does not expose every methodological weakness. (PMID 42233037 (https://pubmed.ncbi.nlm.nih.gov/42233037/)) - Joint pain and hidradenitis suppurativa: a retrospective cohort study.: The abstract describes a retrospective cohort study. In practical terms, it focuses on this question or finding: Joint pain was reported by 37% of patients with hidradenitis suppurativa (HS) at our single-centre HS clinic. However, only one-quarter of those reporting joint pain had a diagnosis of arthritis. What makes it notable here is that it approaches HS through pain, comorbidities. For context on how often the joints are involved in HS and when a referral may help, see our overview of the underdiagnosed joint involvement (/en/blog/spondyloarthritis-acne-inversa-joint-involvement/). The main limitation to keep in mind is: As an observational analysis, it can describe associations but cannot securely prove cause and effect. (PMID 42222703 (https://pubmed.ncbi.nlm.nih.gov/42222703/)) - A survey of UK-based dermatologists and Outpatient Parenteral Antimicrobial Therapy centres to evaluate the use of intravenous antibiotics as a treatment for hidradenitis suppurativa.: The abstract describes a survey-based report. In practical terms, it focuses on this question or finding: Case series have indicated that intravenous antibiotics may be effective in severe hidradenitis suppurativa (HS) treatment. This treatment approach is excluded from the British Association of Dermatologists UK HS trea… What makes it notable here is that it approaches HS through surgery, biologics. The main limitation to keep in mind is: Surveys can show practice patterns and opinions, but they do not by themselves show which approach works best for patients. (PMID 42222698 (https://pubmed.ncbi.nlm.nih.gov/42222698/)) - IL-17 treatment and side-effect management: This paper focuses on mucocutaneous candidiasis during bimekizumab therapy for HS. The new angle is practical: how prevention and early management of a known IL-17-pathway adverse event might affect tolerability and treatment persistence. (PMID 42247110 (https://pubmed.ncbi.nlm.nih.gov/42247110/)) - Suicidal ideation in patients with skin conditions: A multicentre European study.: The abstract describes a multicenter study. In practical terms, it focuses on this question or finding: Suicidal ideation is a significant, often overlooked, concern in dermatology. Individuals with skin diseases frequently experience psychological distress, including depression, anxiety, stigma and dissatisfaction with… What makes it notable here is that it approaches HS through quality of life, comorbidities. If the psychological side of living with HS resonates with you, our article on shame, body image, and acne inversa (/en/blog/shame-body-image-acne-inversa/) explores why it is not "just skin." The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42246602 (https://pubmed.ncbi.nlm.nih.gov/42246602/)) Featured publication The featured paper is Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review. in Frontiers in immunology (PMID 42233037 (https://pubmed.ncbi.nlm.nih.gov/42233037/)). The abstract mainly says this: Dietary factors have been suggested to influence inflammatory skin diseases; however, their role in the pathogenesis and clinical course of hidradenitis suppurativa (HS) remains insufficiently understood. Increasing e… Why it stands out: it connects to the priority themes surgery, wound care, comorbidities and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that Its strength depends on the quality and comparability of the included studies, and an abstract does not expose every methodological weakness. What this may mean for patients (carefully, no advice) If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation. But even when a study sounds promising, it usually does not tell you what is right for you personally. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions. What we don’t know / limitations - This update includes only PubMed items with an abstract (without an abstract, safe summarization is limited). - Studies vary widely (design, populations, outcome measures). - This update provides no treatment advice and cannot assess individual risk. Important: decisions belong in clinician conversations This article is an editorial overview and is not medically reviewed. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals. If you would like to compare with the prior roundup, see our earlier HS research update (/en/blog/hs-research-update-2026-06-01/). FAQ Why are there only a few new publications here? This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts. Does a new paper mean my treatment should change? No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person. Why emphasize limitations so much? Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly. Sources & original papers Each point below maps to an original source (PubMed link, plus DOI/PMCID when available). FAQ Why are there only a few new publications here? This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts. Does a new paper mean my treatment should change? No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person. Why emphasize limitations so much? Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly. References 1. Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II. - Dermatology and therapy, 2026 — PMID 42247110 · DOI 10.1007/s13555-026-01790-2 - https://pubmed.ncbi.nlm.nih.gov/42247110/ 2. Suicidal ideation in patients with skin conditions: A multicentre European study. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42246602 · DOI 10.1111/jdv.70523 - https://pubmed.ncbi.nlm.nih.gov/42246602/ 3. Clinical Features of Hidradenitis Suppurativa in Down Syndrome Patients: A Multicenter Spanish Study. - Journal of cutaneous medicine and surgery, 2026 — PMID 42233244 · DOI 10.1177/12034754261453366 - https://pubmed.ncbi.nlm.nih.gov/42233244/ 4. Association between obesity and the risk of skin and soft tissue infections in European populations: A systematic review. - IJID regions, 2026 — PMID 42232142 · DOI 10.1016/j.ijregi.2026.100911 · PMCID PMC13224352 - https://pubmed.ncbi.nlm.nih.gov/42232142/ 5. Joint pain and hidradenitis suppurativa: a retrospective cohort study. - Skin health and disease, 2026 — PMID 42222703 · DOI 10.1093/skinhd/vzag013 · PMCID PMC13220027 - https://pubmed.ncbi.nlm.nih.gov/42222703/ 6. A survey of UK-based dermatologists and Outpatient Parenteral Antimicrobial Therapy centres to evaluate the use of intravenous antibiotics as a treatment for hidradenitis suppurativa. - Skin health and disease, 2026 — PMID 42222698 · DOI 10.1093/skinhd/vzag005 · PMCID PMC13220039 - https://pubmed.ncbi.nlm.nih.gov/42222698/ 7. Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review. - Frontiers in immunology, 2026 — PMID 42233037 · DOI 10.3389/fimmu.2026.1830618 · PMCID PMC13222998 - https://pubmed.ncbi.nlm.nih.gov/42233037/ 8. New-Onset Musculoskeletal Manifestations in Hidradenitis Suppurativa: A Large-Scale Incidence Analysis. - Cureus, 2026 — PMID 42245890 · DOI 10.7759/cureus.108229 · PMCID PMC13231938 - https://pubmed.ncbi.nlm.nih.gov/42245890/